Sphera Funds Management Ltd. Arvinas, Inc. Transaction History

Sphera Funds Management Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $2.73 Million - $11.5 Million	-135,000 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$22.99 - $36.34 $3.1 Million - $4.91 Million	135,000 New	135,000 $3.19 Million
Q2 2020 Aug 13, 2020	SELL	$29.88 - $56.74 $4.36 Million - $8.27 Million	-145,781 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$33.0 - $54.5 $1.75 Million - $2.89 Million	-53,000 Reduced 26.66%	145,781 $5.88 Million
Q4 2019 Feb 13, 2020	SELL	$15.39 - $44.38 $100,035 - $288,470	-6,500 Reduced 3.17%	198,781 $8.17 Million
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $115,358 - $172,026	7,228 Added 3.65%	205,281 $0
Q1 2019 May 15, 2019	SELL	$13.55 - $23.79 $989,150 - $1.74 Million	-73,000 Reduced 26.93%	198,053 $2.92 Million
Q4 2018 Feb 14, 2019	BUY	$11.19 - $18.56 $347,483 - $576,343	31,053 Added 12.94%	271,053 $3.48 Million
Q3 2018 Nov 14, 2018	BUY	$16.05 - $16.87 $3.85 Million - $4.05 Million	240,000 New	240,000 $4.05 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.